Cardiovascular Endocrinology & Metabolism
Pharmacol Res 216: 107770
Expected progression: Weeks one to two: Pain reduction, improved sleep (if night pain present) Weeks three to four: Increased range of motion, tolerance of rehab exercises improves Weeks five to eight: Significant functional improvement, return to activities Weeks eight to twelve: Continued tissue remodeling and strengthening For more on the general approach to peptides for joint pain , our dedicated guide covers the full landscape of options
the net glycaemic effect of retatrutide depends on the balance between these actions and the dominant GLP-1/GIP-mediated insulin response
Enrolling Overweight Obesity Drug: Placebo matching BI 3034701 Drug: BI 3034701 AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea
Note: If you are taking a GLP-1 medication and experience severe, localized abdominal pain that does not improve, do not assume it is just a side effect